This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05450692
Recruitment Status : Recruiting
First Posted : July 11, 2022
Last Update Posted : February 16, 2024
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Condition or disease Intervention/treatment Phase
Advanced or Metastatic Non-Small Cell Lung Cancer Drug: Ceralasertib Drug: Durvalumab Drug: Docetaxel Phase 3

Detailed Description:

This study will consist of two treatment arms (Groups A and B).

Participants will be randomised in a 1:1 ratio to one of the two treatment groups:

  • Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously.
  • Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 580 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Actual Study Start Date : September 15, 2022
Estimated Primary Completion Date : May 22, 2025
Estimated Study Completion Date : May 22, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Group A: Ceralasertib plus durvalumab combination therapy
Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.
Drug: Ceralasertib
Participants will receive ceralasertib oral tablets.

Drug: Durvalumab
Participants will receive durvalumab as an intravenous infusion.

Active Comparator: Group B: Docetaxel monotherapy
Participants will be administered docetaxel (standard of care) administered intravenously.
Drug: Docetaxel
Participants will received docetaxel as an intravenous infusion.




Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years) ]
    The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS (HR with 95% CI and p-value) in participants with advanced NSCLC after second- or third-line therapy and without actionable genomic alterations. OS is defined as time from randomisation until the date of death due to any cause.


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Up to 3 years ]
    PFS will be defined as the time from the date of randomisation until the date of objective PD.

  2. Objective Response Rate (ORR) [ Time Frame: Up to 3 years ]
    ORR is defined as the proportion of participant who have a Complete Response (CR) or Partial Response (PR) per RECIST 1.1.

  3. Duration of Response (DoR) [ Time Frame: Up to 3 years ]
    DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1.

  4. Time To Response (TTR) [ Time Frame: Up to 3 years ]
    TTR is defined as the time from randomisation until the date of first documented objective response.

  5. Disease Control Rate (DCR) [ Time Frame: At Week 18 ]
    DCR at 18 weeks is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) for at least 17 weeks.

  6. Time to second progression or death (PFS2) [ Time Frame: Up to 3 years ]
    Time from randomisation to PFS2 will be defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

  7. Overall Survival (OS) at 12 months [ Time Frame: At 12 months ]
    OS is defined as time from randomisation until the data of death due to any cause.

  8. Time To Deterioration (TTD) of health-related quality of life (QoL) [ Time Frame: Up to 3 years ]
    TTD is defined as the time from randomisation until the date of first confirmed deterioration.

  9. TTD of physical function [ Time Frame: Up to 3 years ]
    TTD in physical functioning is measured by the EORTC QLQ-C30 Physical Function subscale of the EORTC QLQ-C30.

  10. Plasma concentrations for ceralasertib plus durvalumab combination therapy [ Time Frame: Up to 3 years ]
    The PK plasma concentration of ceralasertib when administered in combination with durvalumab will be assessed.

  11. Number of participants with Adverse Evens (AEs) [ Time Frame: Up to 3 years ]
    The safety and tolerability of ceralasertib plus durvalumab combination therapy as compared with docetaxel will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically documented NSCLC that is locally advanced or metastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.
  • Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.
  • Documented radiological PD whilst on or after receiving the most recent treatment regimen.
  • Eligible for second- or third-line therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC either separately or in combination.
  • Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0 or 1.
  • Adequate organ function and marrow reserve
  • Minimum life expectancy of 12 weeks.
  • Body weight > 30 kg and no cancer-associated cachexia.
  • Negative pregnancy test (serum test) for women of childbearing potential (WOCBP).

Exclusion Criteria:

  • Participant with mixed SCLC and NSCLC histology.
  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention.
  • Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.
  • Participants:

    1. Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.
    2. All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.
    3. Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
    4. Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
  • Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.
  • Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05450692


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Show Show 210 study locations
Sponsors and Collaborators
AstraZeneca
Parexel
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT05450692    
Other Study ID Numbers: D533BC00001
2022-000493-26 ( EudraCT Number )
First Posted: July 11, 2022    Key Record Dates
Last Update Posted: February 16, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Durvalumab
Ceralasertib
Docetaxel
Lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Durvalumab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological